Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors

Conclusions Idasanutlin demonstrated dose- and schedule-dependent p53 activation with durable disease stabilization in some patients. Based on these findings, the QD × 5 schedule was selected for further development.Trial registrationNCT01462175 (ClinicalTrials.gov), October 31, 2011.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research